uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

uniQure (NASDAQ:QURE) posted its earnings results on Tuesday. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03, FiscalAI reports. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $4.49 million.

Here are the key takeaways from uniQure’s conference call:

• uniQure has a scheduled Type B meeting with the FDA later this quarter to discuss the statistical analysis plan for the 4?year AMT?130 data and design elements of a new study, and plans a MAA submission in the U.K. in Q3 based on 3?year data, creating near?term regulatory catalysts.
• Enrollment in the Phase I/II?A study of AMT?260 for refractory mesial temporal lobe epilepsy is on track, with safety, tolerability and seizure?frequency results from the first 6?patient cohort (?6 months) expected in Q2 and the company targeting a meaningful seizure?reduction signal to guide dose selection.
• AMT?191 (Fabry) showed dose?dependent, durable increases in alpha?gal A and all 11 dosed patients have discontinued enzyme replacement therapy, but dosing at mid/high cohorts was paused after two asymptomatic grade?3 liver enzyme elevations and the program is continuing follow?up while dosing at the low dose.
• The company has discontinued development of AMT?162 for SOD1?ALS after a serious adverse event of dorsal root ganglia toxicity in one patient, and will continue safety follow?up for the five dosed patients.
• uniQure ended Q1 with $586.6 million in cash, equivalents and investments and states this is sufficient to fund operations into H2 2029, though management noted future prioritization will be required to preserve the runway.

uniQure Stock Up 0.4%

uniQure stock traded up $0.08 during mid-day trading on Tuesday, hitting $20.76. The company had a trading volume of 532,477 shares, compared to its average volume of 2,825,579. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock’s 50 day moving average price is $16.75 and its two-hundred day moving average price is $25.53. uniQure has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a market capitalization of $1.31 billion, a PE ratio of -6.00 and a beta of 0.87.

Analysts Set New Price Targets

QURE has been the topic of several research analyst reports. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Chardan Capital upped their price target on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Barclays reduced their price target on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of uniQure in a research note on Tuesday, March 10th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $43.33.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 14,581 shares of uniQure stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the transaction, the chief executive officer directly owned 660,658 shares in the company, valued at approximately $5,985,561.48. This trade represents a 2.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares in the company, valued at $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 49,396 shares of company stock valued at $722,734. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Smartleaf Asset Management LLC purchased a new position in uniQure during the 4th quarter worth $48,000. CIBC Private Wealth Group LLC purchased a new position in uniQure during the 3rd quarter worth $50,000. Ensign Peak Advisors Inc grew its stake in uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares during the last quarter. Knott David M Jr grew its stake in uniQure by 100.0% during the 4th quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company’s stock worth $96,000 after buying an additional 2,000 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,538 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.